The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Should we move beyond JAK inhibitors in MPNs?
In this video, Rami Komrokji, MD, Moffitt Cancer Center, Tampa, FL, briefly comments on a panel discussion that covered novel pathways and targets in myeloproliferative neoplasms (MPNs) and the potential of moving beyond JAK inhibitors for disease modification. Dr Komrokji highlights the central role of JAK inhibitors in treating MPNs, emphasizing that the focus should be on improving them and developing the next generation of agents in this drug class. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
